Afficher la notice abrégée

LAVR-289, an Orally Bioavailable Inhibitor of Adenovirus Replication In Vitro and In Vivo

dc.rights.licenseopenen_US
dc.contributor.authorQUENTIN-FROIGNANT, Charlotte
dc.contributor.authorTOLLEFSON, Ann E
dc.contributor.authorCLINE-SMITH, Anna
dc.contributor.authorKAPPLER-GRATIAS, Sandrine
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorLANDREIN, Nicolas
dc.contributor.authorROY, Vincent
dc.contributor.authorAGROFOGLIO, Luigi A
dc.contributor.authorTOTH, Karoly
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorWODRICH, Harald
dc.contributor.authorGALLARDO, Franck
dc.date.accessioned2025-05-27T07:35:22Z
dc.date.available2025-05-27T07:35:22Z
dc.date.issued2025-05-19
dc.identifier.issn2373-8227en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206732
dc.description.abstractEnAdenoviruses are responsible for a range of pathologies, including respiratory infections in children. Although most adenovirus infections are self-resolving, they can cause serious illness, particularly in immunocompromised individuals. There is currently no approved treatment for adenovirus infections. Here, we report on the antiviral activity of LAVR-289, a broad-spectrum acyclonucleoside phosphonate exhibiting potent efficacy against several adenovirus serotypes, comparable to that of brincidofovir. LAVR-289 specifically inhibits viral replication, blocking the formation of viral replication centers and preventing late protein expression without affecting viral entry or delivery of viral genomes to the nucleus. , using immunocompromised Syrian hamsters infected with HAdV-C6, oral administration of LAVR-289 resulted in 100% animal survival. These results suggest that LAVR-289 holds promise as a potential therapy for adenovirus infections paving the way for a future treatment of immunocompromised patients.
dc.language.isoENen_US
dc.subject.enAcyclic nucleoside phosphonate prodrug; Adenovirus infection; Antiviral; LAVR-289; in vivo
dc.title.enLAVR-289, an Orally Bioavailable Inhibitor of Adenovirus Replication In Vitro and In Vivo
dc.title.alternativeACS Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1021/acsinfecdis.5c00170en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
dc.identifier.pubmed40384232en_US
bordeaux.journalACS Infectious Diseasesen_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-05086102
hal.version1
hal.date.transferred2025-05-27T07:35:25Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=ACS%20Infectious%20Diseases&rft.date=2025-05-19&rft.eissn=2373-8227&rft.issn=2373-8227&rft.au=QUENTIN-FROIGNANT,%20Charlotte&TOLLEFSON,%20Ann%20E&CLINE-SMITH,%20Anna&KAPPLER-GRATIAS,%20Sandrine&LANDREIN,%20Nicolas&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée